Trial reportArchives of disease in childhood2003
Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis.
Trial report in Archives of disease in childhood, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Appetite stimulants for people with cystic fibrosis.The Cochrane database of systematic reviews · 2022Pooled it
- Recombinant growth hormone therapy for cystic fibrosis in children and young adults.The Cochrane database of systematic reviews · 2021Pooled it
- Recombinant growth hormone therapy for cystic fibrosis in children and young adults.The Cochrane database of systematic reviews · 2018Pooled it
- Recombinant growth hormone therapy for cystic fibrosis in children and young adults.The Cochrane database of systematic reviews · 2013Pooled it
- A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis.Pediatric pulmonology · 2012Trial
- Case report of a Hispanic female with cystic fibrosis and short stature.Respiratory medicine case reports · 2022Article
- Growth failure and treatment in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019Review
- A roadmap to the brittle bones of cystic fibrosis.Journal of osteoporosis · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy and safety of treatment with recombinant growth hormone (rGH) in patients with cystic fibrosis (CF).
methodsTwenty patients with CF (aged 10-23 years) were randomised to age and sex matched treatment and control groups. The treatment group received daily subcutaneous injections of 1 IU/kg/wk rGH for 12 months. Pulmonary function (forced expiratory volume in one second (FEV1) and airway resistance), exercise capacity measured with a bicycle ergometer, body composition (dual energy x ray absorptiometry), and weight were assessed at the beginning of the study and after 6 and 12 months.
resultsrGH treatment did not improve weight and pulmonary function, but lean body mass increased significantly in the treatment group. Exercise capacity increased in the treatment group from 143 (16) W (mean (SD)) to 164 (19) W after 12 months of rGH treatment.
conclusionTreatment of CF patients with rGH for one year improved the exercise capacity significantly but not pulmonary function. The improved exercise capacity needs confirmation in a larger population before such an expensive treatment is justified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.